Jed Dorsheimer, William Blair analyst, joins 'The Exchange' to discuss Tesla's chip deal with Samsung and what it means for ...

Vertiv Holdings (NYSE:VRT) on Monday was rated Outperform in new research coverage by analysts at investment firm William ...

In addition, The Allstate Corporation (NYSE:ALL) is taking advantage of a far better auto loss environment and employing ...

In its own communique issued shortly after the FDA’s, Sarepta elaborated on the situation and confirmed a Roche statement to ...

Brazilian authorities said the death was unlikely to have been caused by Elevidys and was instead more in line with severe ...

The company didn’t share specific data for the molecule, gefurulimab, but said it hit all endpoints in the Phase III PREVAIL ...

William Blair analysts lowered their rating on Ameriprise stock to Market Perform from Outperform Friday following the financial services firm’s second-quarter report.

Palantir Technologies Inc. (NASDAQ:PLTR) is one of the best 52-week high stocks to buy now. On July 21, the stock was a big ...

A key driver of Tesla's profit is disappearing fast as the U.S. government changes policies on an environmental asset known ...

Tesla (TSLA) is set to report second quarter earnings on Wednesday afternoon. William Blair group head of energy and power technologies sector Jed Dorsheimer joins Market Domination with Josh Lipton ...

For years, Tesla has earned billions of dollars from its competitors just for selling electric vehicles. But that windfall is about to go away, just when the company may need it the most.

Sarepta would need to conduct new analyses to validate the safety of Elevidys—which has had U.S. shipments paused by the company over a mounting string of controversies—to the FDA, Endpoints News and ...